Value for Money
Pharma needs to make the case for the value it brings to the table – and payers need to listen.
In a complex stakeholder environment, there are misunderstandings about the expense of drugs, a large gap between regulators and payers, and innovation in R&D still needs to be encouraged – these were among the main topics of discussion at eyeforpharma’s Oncology Market Access & Pricing 2016 in Philadelphia.
In this video, Dr. Soeren Mattke of Rand Corporation gives his views on the importance of scientists being able to communicate their ideas to the public, while Bill McGivney of McGivney Global suggests that there is a need to figure out how to pay for the incentives which are required to develop game-changing treatments.
Meanwhile, Anna Forsythe of Purple Squirrel says that payers need to reframe the evidence they are looking for and cancer survivor Jack Whelan explains exactly why he is so keen to explore what’s happening in research and clinical trials.
Since you're here...
... and value our content, you should sign-up to our newsletter. Sign up here